NCT04757259 2024-03-19
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
Alexion Pharmaceuticals, Inc.
No longer available
Alexion Pharmaceuticals, Inc.
Seagen Inc.
Molecular Templates, Inc.
Sanofi